TY - JOUR
T1 - Revisiting Excitotoxicity in Traumatic Brain Injury: From Bench to Bedside
AU - Baracaldo-Santamaría, Daniela
AU - Ariza-Salamanca, Daniel Felipe
AU - Corrales-Hernández, María Gabriela
AU - Pachón-Londoño, Maria José
AU - Hernandez-Duarte, Isabella
AU - Calderon-Ospina, Carlos Alberto
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality. Consequences vary from mild cognitive impairment to death and, no matter the severity of subsequent sequelae, it represents a high burden for affected patients and for the health care system. Brain trauma can cause neuronal death through mechanical forces that disrupt cell architecture, and other secondary consequences through mechanisms such as inflammation, oxidative stress, programmed cell death, and, most importantly, excitotoxicity. This review aims to provide a comprehensive understanding of the many classical and novel pathways implicated in tissue damage following TBI. We summarize the preclinical evidence of potential therapeutic interventions and describe the available clinical evaluation of novel drug targets such as vitamin B12 and ifenprodil, among others.
AB - Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality. Consequences vary from mild cognitive impairment to death and, no matter the severity of subsequent sequelae, it represents a high burden for affected patients and for the health care system. Brain trauma can cause neuronal death through mechanical forces that disrupt cell architecture, and other secondary consequences through mechanisms such as inflammation, oxidative stress, programmed cell death, and, most importantly, excitotoxicity. This review aims to provide a comprehensive understanding of the many classical and novel pathways implicated in tissue damage following TBI. We summarize the preclinical evidence of potential therapeutic interventions and describe the available clinical evaluation of novel drug targets such as vitamin B12 and ifenprodil, among others.
UR - http://www.scopus.com/inward/record.url?scp=85122463641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122463641&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14010152
DO - 10.3390/pharmaceutics14010152
M3 - Review article
C2 - 35057048
AN - SCOPUS:85122463641
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 1
M1 - 152
ER -